MPM BIOVENTURES 2018, L.P.

SEC Form 4 insider transaction history, cleaned and classified by FilingIQ.

Total trades
16
Last 180 days
12
Last trade
Sep 9, 2026

Recent tickers traded

AKTS TRDA

Latest filings by MPM BIOVENTURES 2018, L.P.

TRDA Entrada Therapeutics, Inc.
S Sep 8, 2026
TRDA Entrada Therapeutics, Inc.
S Sep 3, 2026
TRDA Entrada Therapeutics, Inc.
S Aug 31, 2026
TRDA Entrada Therapeutics, Inc.
S Aug 25, 2026

Most recent disclosures. Sign up to filter by transaction code, company or dollar value.

Activity overview

FilingIQ has indexed 16 SEC Form 4 insider transactions associated with MPM BIOVENTURES 2018, L.P.. The most recent transaction is dated Sep 9, 2026.

View live filings on FilingIQ Raw Form 4 on SEC EDGAR

Frequently asked

How many Form 4 transactions has MPM BIOVENTURES 2018, L.P. filed?
FilingIQ has indexed 16 SEC Form 4 insider transactions associated with MPM BIOVENTURES 2018, L.P.. The most recent transaction is dated Sep 9, 2026. Every filing sources back directly to SEC EDGAR.
What does FilingIQ show for MPM BIOVENTURES 2018, L.P.'s trades?
Each open-market purchase and sale carries the same seven facts: its size in MPM BIOVENTURES 2018, L.P.'s own history at that company, the change in holdings, the previous trade, other insiders at the company in the 30 days before, the Rule 10b5-1 plan answer, the reporting time and other companies. FilingIQ does not rate the trades. The rules are at /methodology.
Which companies has MPM BIOVENTURES 2018, L.P. traded?
Most recent trading activity covers AKTS, TRDA. The full Form 4 history including older issuers is available on the FilingIQ web app.
Where does FilingIQ's insider data come from?
Every Form 4 transaction shown on this page is parsed directly from SEC EDGAR XML filings. Insider identity is normalized across CIK changes, name spellings, and indirect / related-party reporting.

Methodology & sources

All Form 4 transactions parsed directly from public SEC EDGAR XML filings. How lines are classified and which facts FilingIQ adds is documented on methodology. Compiled by Thomas Kraaibeek. Not investment advice; see disclaimer.